These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36967847)

  • 21. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effect of human mini-dystrophin in transgenic mdx mice improves muscle physiological function.
    Chu X; Li J; Qiao C; Wang J; Wang Y; Jiang XC; You H; Xiao X; Wang B
    FASEB J; 2021 Jun; 35(6):e21628. PubMed ID: 33982338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tetrahydrobiopterin synthesis and metabolism is impaired in dystrophin-deficient mdx mice and humans.
    Lindsay A; Kemp B; Larson AA; Baumann CW; McCourt PM; Holm J; Karachunski P; Lowe DA; Ervasti JM
    Acta Physiol (Oxf); 2021 Apr; 231(4):e13627. PubMed ID: 33580591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy.
    Chun JL; O'Brien R; Song MH; Wondrasch BF; Berry SE
    Stem Cells Transl Med; 2013 Jan; 2(1):68-80. PubMed ID: 23283493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
    Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P
    Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term human IgG treatment improves heart and muscle function in a mouse model of Duchenne muscular dystrophy.
    Zschüntzsch J; Jouvenal PV; Zhang Y; Klinker F; Tiburcy M; Liebetanz D; Malzahn D; Brinkmeier H; Schmidt J
    J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):1018-1031. PubMed ID: 32436338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small Fractions of Muscular Dystrophy Embryonic Stem Cells Yield Severe Cardiac and Skeletal Muscle Defects in Adult Mouse Chimeras.
    Gonzalez JP; Kyrychenko S; Kyrychenko V; Schneider JS; Granier CJ; Himelman E; Lahey KC; Zhao Q; Yehia G; Tao YX; Bhaumik M; Shirokova N; Fraidenraich D
    Stem Cells; 2017 Mar; 35(3):597-610. PubMed ID: 27734557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy.
    Abou-Samra M; Selvais CM; Boursereau R; Lecompte S; Noel L; Brichard SM
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):518-533. PubMed ID: 31965757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy.
    Mucha O; Podkalicka P; Kaziród K; Samborowska E; Dulak J; Łoboda A
    Skelet Muscle; 2021 Sep; 11(1):21. PubMed ID: 34479633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ifetroban reduces coronary artery dysfunction in a mouse model of Duchenne muscular dystrophy.
    Mitchell R; Frederick NE; Holzman ER; Agobe F; Allaway HCM; Bagher P
    Am J Physiol Heart Circ Physiol; 2021 Jul; 321(1):H52-H58. PubMed ID: 34048282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced dimethylarginine degradation improves coronary flow reserve and exercise tolerance in Duchenne muscular dystrophy carrier mice.
    Garbincius JF; Merz LE; Cuttitta AJ; Bayne KV; Schrade S; Armstead EA; Converso-Baran KL; Whitesall SE; D'Alecy LG; Michele DE
    Am J Physiol Heart Circ Physiol; 2020 Sep; 319(3):H582-H603. PubMed ID: 32762558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L-type Ca2+ channel function is linked to dystrophin expression in mammalian muscle.
    Friedrich O; von Wegner F; Chamberlain JS; Fink RH; Rohrbach P
    PLoS One; 2008 Mar; 3(3):e1762. PubMed ID: 18516256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dystrophin delivery in dystrophin-deficient DMDmdx skeletal muscle by isogenic muscle-derived stem cell transplantation.
    Ikezawa M; Cao B; Qu Z; Peng H; Xiao X; Pruchnic R; Kimura S; Miike T; Huard J
    Hum Gene Ther; 2003 Nov; 14(16):1535-46. PubMed ID: 14577915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function.
    Lindsay A; Schmiechen A; Chamberlain CM; Ervasti JM; Lowe DA
    Exp Physiol; 2018 Jul; 103(7):995-1009. PubMed ID: 29791760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Muscular dystrophy begins early in embryonic development deriving from stem cell loss and disrupted skeletal muscle formation.
    Merrick D; Stadler LK; Larner D; Smith J
    Dis Model Mech; 2009; 2(7-8):374-88. PubMed ID: 19535499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
    Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
    Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibiting the inflammasome with MCC950 counteracts muscle pyroptosis and improves Duchenne muscular dystrophy.
    Dubuisson N; Davis-López de Carrizosa MA; Versele R; Selvais CM; Noel L; Van den Bergh PYD; Brichard SM; Abou-Samra M
    Front Immunol; 2022; 13():1049076. PubMed ID: 36569900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exosome-Derived Dystrophin from Allograft Myogenic Progenitors Improves Cardiac Function in Duchenne Muscular Dystrophic Mice.
    Su X; Jin Y; Shen Y; Ju C; Cai J; Liu Y; Kim IM; Wang Y; Yu H; Weintraub NL; Jiang M; Tang Y
    J Cardiovasc Transl Res; 2018 Oct; 11(5):412-419. PubMed ID: 30155598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.
    Niezgoda A; Biegański G; Wachowiak J; Czarnota J; Siemionow K; Heydemann A; Ziemiecka A; Sikorska MH; Bożyk K; Siemionow M
    Arch Immunol Ther Exp (Warsz); 2023 Nov; 71(1):24. PubMed ID: 37999748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vector-mediated expression of muscle specific kinase restores specific force to muscles in the mdx mouse model of Duchenne muscular dystrophy.
    Ban J; Beqaj B; Phillips WD
    Exp Physiol; 2021 Aug; 106(8):1794-1805. PubMed ID: 34114278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.